NivolumabGrade 3 Hepatitis and grade 4 colitis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2032卷 / 1期

关键词：

D O I：

10.1007/s40278-024-70027-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：366 / 366

相关论文

共 50 条

[41] PembrolizumabRash and colitis: 2 case reports
Reactions Weekly, 2021, 1875 (1) : 285 - 285
[42] HydroxycarbamideFever and hepatitis: 4 case reports
Reactions Weekly, 1998, 731 (1) : 7 - 7
[43] PembrolizumabDiarrhoea and colitis: 2 case reports
Reactions Weekly, 2023, 1959 (1) : 539 - 539
[44] MethylprednisoloneToxic hepatitis: 4 case reports
Reactions Weekly, 2015, 1575 (1) : 152 - 152
[45] MoxifloxacinSevere pseudomembranous colitis: 4 case reports
Reactions Weekly, 2009, 1234 (1) : 27 - 27
[46] Ipilimumab/NivolumabGrade 1 hypothyroidism and grade 3 secondary adrenal insufficiency
Reactions Weekly, 2023, 1985 (1) : 272 - 272
[47] IpilimumabImmune related colitis: 3 case reports
Reactions Weekly, 2020, 1785 (1) : 294 - 294
[48] TocilizumabBacterial infections and colitis: 3 case reports
Reactions Weekly, 2022, 1927 (1) : 495 - 495
[49] Ipilimumab/NivolumabColitis of grade3, adrenal insufficiency of grade 3 and renal dysfunction of grade 2: 3 case reports
Reactions Weekly, 2024, 2035 (1) : 251 - 251
[50] TiclopidineLymphocytic colitis and diarrhoea: 3 case reports
Reactions Weekly, 1998, 708 (1) : 11 - 11

← 1 2 3 4 5 →